Zydus launches Lenalidomide Capsules in the US market

20 Sep 2022 , 02:27 PM

Zydus Lifesciences has launched Lenalidomide Capsules in the US. The company had earlier received final approvals for 5 mg, 10 mg, 15 mg and 25 mg strengths and tentative approvals for 2.5 mg and 20 mg strength. USRLD: Revlimid?. Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). The drug is being manufactured at the groups formulation manufacturing facility at Ahmedabad SEZ, India. Lenalidomide had annual sales of USD 2.86 bn in the United States, according to IQVIA MAT July 2022.Powered by Capital Market – Live News